Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock By Investing.com

NodeGuardian · 2026-04-11T16:40:10+00:00

Daphne Karydas of Mineralys Therapeutics sold 3,000 shares for $75,000 and exercised options for the same amount. Despite strong stock performance and exceeding earnings expectations, analysts warn the stock may be overvalued.

NodeGuardian

2026-04-11 16:40:10

Abstract generation in progress

Daphne Karydas, a director at Mineralys Therapeutics Inc (MLYS), sold 3,000 shares of common stock for $75,000 and exercised options to acquire 3,000 shares for $36,060 through a pre-arranged trading plan. This transaction occurred as MLYS stock has shown significant momentum, returning 92.6% over the past year, although InvestingPro analysis suggests it may be overvalued despite high analyst price targets. The company recently exceeded Q4 2025 earnings expectations and is advancing its lead drug lorundrostat, alongside a new Chief Legal Officer appointment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.